Innovacell (TSE:504A) EV-to-FCF: (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:504A Innovacell Inc TSE:504A
10 GF Score
Price 円453.00
View Full Analysis

What is Innovacell EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Innovacell's Enterprise Value is 円10,919.15 Mil. Innovacell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.00 Mil. Therefore, Innovacell's EV-to-FCF for today is .

The historical rank and industry rank for Innovacell's EV-to-FCF or its related term are showing as below:

TSE:504A' s EV-to-FCF Range Over the Past 10 Years
Min: -6.19   Med: 0   Max: 0
Current: -6.19
TSE:504A's EV-to-FCF is ranked worse than
100% of 335 companies
in the Biotechnology industry
Industry Median: 15.34 vs TSE:504A: -6.19

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-14), Innovacell's stock price is 円453.00. Innovacell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was 円-70.311. Therefore, Innovacell's PE Ratio (TTM) for today is At Loss.

Innovacell  (TSE:504A) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Innovacell's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=453.00/-70.311
=At Loss

Innovacell's share price for today is 円453.00.
Innovacell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-70.311.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Innovacell EV-to-FCF Related Terms

Innovacell EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Innovacell's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovacell EV-to-FCF Chart

Innovacell Annual Data
Trend Dec23 Dec24 Dec25
EV-to-FCF
0.00 0.00 0.00

Innovacell Quarterly Data
Dec23 Dec24 Sep25 Dec25 Mar26
EV-to-FCF 0.00 0.00 0.00 0.00 0.00

TSE:504A vs VRTX, REGN, ALNY: EV-to-FCF Comparison

For the Biotechnology subindustry, Innovacell's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovacell EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovacell's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Innovacell's EV-to-FCF falls into.


TSE:504A
10GF Score
Innovacell Inc TSE:504A
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovacell EV-to-FCF Calculation

Innovacell's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10919.147/0
=

Innovacell's current Enterprise Value is 円10,919.15 Mil.
Innovacell's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovacell Business Description

Address 3-5-11 Kamiosaki, Meguro Villa Garden, 5th floor, Shinagawa-ku, Tokyo, JPN, 141-0021
Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Its activities include researching potential therapeutic candidates, developing formulations, and commercializing products in the markets. The company is working on the development and commercialization of the following three cell therapy pipelines targeting incontinence (fecal and urinary incontinence): ICEF15, ICEF16, and ICES13.
10GF Score

Get the complete analysis for TSE:504A

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円453.00
Price